Last reviewed · How we verify
Comparator: Antidiabetic Standard of Care
Comparator: Antidiabetic Standard of Care is a Small molecule drug developed by Merck Sharp & Dohme LLC. It is currently in Phase 3 development for Type 2 diabetes mellitus (as standard-of-care comparator in phase 3 trials).
This is a comparator arm representing standard-of-care antidiabetic therapy used as a control reference in clinical trials, not a specific drug with a single mechanism.
This is a comparator arm representing standard-of-care antidiabetic therapy used as a control reference in clinical trials, not a specific drug with a single mechanism. Used for Type 2 diabetes mellitus (as standard-of-care comparator in phase 3 trials).
At a glance
| Generic name | Comparator: Antidiabetic Standard of Care |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
As a comparator standard of care, this represents the established antidiabetic treatment regimen (typically metformin, sulfonylureas, DPP-4 inhibitors, GLP-1 agonists, insulin, or combinations thereof) against which investigational antidiabetic agents are evaluated. The specific mechanism depends on which standard-of-care agents are included in the comparator arm for a given trial.
Approved indications
- Type 2 diabetes mellitus (as standard-of-care comparator in phase 3 trials)
Common side effects
Key clinical trials
- Transformative Research in Diabetic Nephropathy 2.0
- Semi-individualised Chinese Medicine Treatment as an Adjuvant Management for Diabetic Nephropathy (PHASE2, PHASE3)
- Efficacy, Safety and Response Predictors of Adjuvant Astragalus Therapy for Diabetic Kidney Disease (PHASE2, PHASE3)
- Ertugliflozin Versus Hydrochlorothiazide in Reducing Sympathetic Neural Overactivity in Patients With Hypertension and Recently-diagnosed Type 2 Diabetes. (PHASE4)
- Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (0431-189) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Comparator: Antidiabetic Standard of Care CI brief — competitive landscape report
- Comparator: Antidiabetic Standard of Care updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI
Frequently asked questions about Comparator: Antidiabetic Standard of Care
What is Comparator: Antidiabetic Standard of Care?
How does Comparator: Antidiabetic Standard of Care work?
What is Comparator: Antidiabetic Standard of Care used for?
Who makes Comparator: Antidiabetic Standard of Care?
What development phase is Comparator: Antidiabetic Standard of Care in?
Related
- Manufacturer: Merck Sharp & Dohme LLC — full pipeline
- Therapeutic area: All drugs in Diabetes
- Indication: Drugs for Type 2 diabetes mellitus (as standard-of-care comparator in phase 3 trials)
- Compare: Comparator: Antidiabetic Standard of Care vs similar drugs
- Pricing: Comparator: Antidiabetic Standard of Care cost, discount & access